Show simple item record

dc.contributor.authorCox, SRen_US
dc.contributor.authorLindsay, JOen_US
dc.contributor.authorFromentin, Sen_US
dc.contributor.authorStagg, AJen_US
dc.contributor.authorMcCarthy, NEen_US
dc.contributor.authorGalleron, Nen_US
dc.contributor.authorIbraim, SBen_US
dc.contributor.authorRoume, Hen_US
dc.contributor.authorLevenez, Fen_US
dc.contributor.authorPons, Nen_US
dc.contributor.authorMaziers, Nen_US
dc.contributor.authorLomer, MCen_US
dc.contributor.authorEhrlich, SDen_US
dc.contributor.authorIrving, PMen_US
dc.contributor.authorWhelan, Ken_US
dc.date.accessioned2019-10-08T07:22:32Z
dc.date.available2019-09-19en_US
dc.date.issued2020-01en_US
dc.identifier.urihttps://qmro.qmul.ac.uk/xmlui/handle/123456789/60036
dc.description.abstractBACKGROUND & AIMS: There is limited evidence that a diet low in fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (FODMAPs) reduces gut symptoms in quiescent inflammatory bowel disease (IBD). We performed a randomized, controlled trial to investigate the effects of a low FODMAP diet on persistent gut symptoms, the intestinal microbiome, and circulating markers of inflammation in patients with quiescent IBD. METHODS: We performed a single-blind trial of 52 patients with quiescent Crohn's disease or ulcerative colitis and persistent gut symptoms at 2 large gastroenterology clinics in the United Kingdom. Patients were randomly assigned to groups that followed a diet low in FODMAPs (n = 27) or a control diet (n = 25), with dietary advice, for 4 weeks. Gut symptoms and health-related quality of life were measured using validated questionnaires. Stool and blood samples were collected at baseline and end of trial. We assessed fecal microbiome composition and function using shotgun metagenomic sequencing and phenotypes of T cells in blood using flow cytometry. RESULTS: A higher proportion of patients reported adequate relief of gut symptoms following the low FODMAP diet (14/27, 52%) than the control diet (4/25, 16%, P=.007). Patients had a greater reduction in irritable bowel syndrome severity scores following the low FODMAP diet (mean reduction of 67; standard error, 78) than the control diet (mean reduction of 34; standard error, 50), although this difference was not statistically significant (P = .075). Following the low FODMAP diet, patients had higher health-related quality of life scores (81.9 ± 1.2) than patients on the control diet (78.3 ± 1.2, P = .042). A targeted analysis revealed that in stool samples collected at the end of the study period, patients on the low FODMAP diet had significantly lower abundance of Bifidobacterium adolescentis, Bifidobacterium longum, and Faecalibacterium prausnitzii than patients on control diet. However, microbiome diversity and markers of inflammation did not differ significantly between groups. CONCLUSIONS: In a trial of the low FODMAP diet vs a control diet in patients with quiescent IBD, we found no significant difference after 4 weeks in change in irritable bowel syndrome severity scores, but significant improvements in specific symptom scores and numbers reporting adequate symptom relief. The low FODMAP diet reduced fecal abundance of microbes believed to regulate the immune response, compared with the control diet, but had no significant effect on markers of inflammation. We conclude that a 4-week diet low in FODMAPs is safe and effective for managing persistent gut symptoms in patients with quiescent IBD. www.isrctn.com no.: ISRCTN17061468.en_US
dc.format.extent176 - 188.e7en_US
dc.languageengen_US
dc.language.isoenen_US
dc.relation.ispartofGastroenterologyen_US
dc.rights© 2019. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectCDen_US
dc.subjectHR-QOLen_US
dc.subjectIBSen_US
dc.subjectUCen_US
dc.subjectAdulten_US
dc.subjectBacteriaen_US
dc.subjectBiomarkersen_US
dc.subjectDiet, Carbohydrate-Restricteden_US
dc.subjectDisaccharidesen_US
dc.subjectFecesen_US
dc.subjectFemaleen_US
dc.subjectGastrointestinal Microbiomeen_US
dc.subjectHumansen_US
dc.subjectInflammatory Bowel Diseasesen_US
dc.subjectMaleen_US
dc.subjectMiddle Ageden_US
dc.subjectMonosaccharidesen_US
dc.subjectQuality of Lifeen_US
dc.subjectSeverity of Illness Indexen_US
dc.subjectSingle-Blind Methoden_US
dc.subjectTreatment Outcomeen_US
dc.subjectUnited Kingdomen_US
dc.subjectYoung Adulten_US
dc.titleEffects of Low FODMAP Diet on Symptoms, Fecal Microbiome, and Markers of Inflammation in Patients With Quiescent Inflammatory Bowel Disease in a Randomized Trial.en_US
dc.typeArticle
dc.identifier.doi10.1053/j.gastro.2019.09.024en_US
pubs.author-urlhttps://www.ncbi.nlm.nih.gov/pubmed/31586453en_US
pubs.issue1en_US
pubs.notesNot knownen_US
pubs.publication-statusPublisheden_US
pubs.volume158en_US
dcterms.dateAccepted2019-09-19en_US
rioxxterms.funderDefault funderen_US
rioxxterms.identifier.projectDefault projecten_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record